Oncology Markets for Tyrosine Kinase Inhibitors


  ONCOLOGY MARKETS for TYROSINE KINASE INHIBITORS 

 NTK522F September 2021 • US$3,850 


 

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. The downstream signal transduction set off by kinases can modify cell growth, migration, differentiation, apoptosis, and death. Constitutive activation or inhibition, either by mutations or other means, can lead to dysregulated signal cascades, which could result in malignancy as well as other pathologies. Commercial activity in the TKI sector is being conducted at a feverish pace, as market participants attempt to seize opportunities that will be short-lived as the wave of TKI approvals continues.

 

Targeted Oncology Therapeutics

 

 

 

Oncology Markets for Tyrosine Kinase Inhibitors – What You Will Learn

• What is the market share of approved therapeutics?
• What is the global supply picture for targeted therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the major Oncology market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation therapeutics?

 

Summary of Contents

 

Executive Summary

 

Biological Drug Market Dynamics

Targeted Oncology Market Segments

Biological Drug Activity by Region

Biological Oncology Market Leaders

 

Breast Cancers

TKI Therapeutics

Clinical Trial Activity

Market Data

 

Hematology Cancers /Leukemias

TKI Therapeutics

Clinical Trial Activity

Market Data

 

Lung Cancers

TKI Therapeutics

Clinical Trial Activity

Market Data

 

Melanomas

TKI Therapeutics

Clinical Trial Activity

Market Data

 

Renal Cell Carcinomas

TKI Therapeutics

Clinical Trial Activity

Market Data

 

Thyroid Cancers

TKI Therapeutics

Clinical Trial Activity

Market Data

 

Leading Biological Drug Companies – Activity by Drug & Segment